Cork MJ, Thaçi D, Eichenfield LF, et al. - Since children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options, researchers reported the pharmacokinetic profile and long‐term safety and effectiveness of dupilumab, a fully human VelocImmune‐derived monoclonal antibody, in children (aged ≥ 6 to < 12 years) with severe AD. Children (aged ≥ 6 to < 12 years) with severe AD were recruited in a global, multicentre, phase IIa, open‐label, ascending‐dose, sequential cohort study and subsequent open‐label extension (OLE) study. Of the 38 children selected, 37 completed phase IIa and 33 continued to the OLE. Nasopharyngitis and AD exacerbation were the most frequent treatment‐emergent adverse events. Such findings suggest that dupilumab should be used as a long-term treatment for children aged ≥ 6 to < 12 years who have severe AD.